[HTML][HTML] Natural peptides for immunological regulation in cancer therapy: mechanism, facts and perspectives
Y Zhang, C Liu, C Wu, L Song - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Cancer incidence and mortality rates are increasing annually. Treatment with surgery,
chemotherapy and radiation therapy (RT) is unsatisfactory because many patients have …
chemotherapy and radiation therapy (RT) is unsatisfactory because many patients have …
Understanding and improving cellular immunotherapies against cancer: From cell-manufacturing to tumor-immune models
The tumor microenvironment (TME) is shaped by dynamic metabolic and immune
interactions between precancerous and cancerous tumor cells and stromal cells like …
interactions between precancerous and cancerous tumor cells and stromal cells like …
Lymphocyte antigen 6 family member E suppresses apoptosis and promotes pancreatic cancer growth and migration via Wnt/β-catenin pathway activation
K Cen, J Zhou, X Yang, Y Guo, Y Xiao - Scientific Reports, 2024 - nature.com
Pancreatic cancer (PC) is the primary cause of cancer-related mortality. Due to the absence
of reliable biomarkers for predicting prognosis or guiding treatment, there is an urgent need …
of reliable biomarkers for predicting prognosis or guiding treatment, there is an urgent need …
Epigenetic and Tumor Microenvironment for Prognosis of patients with gastric Cancer
Z Wu, W Wang, K Zhang, M Fan, R Lin - Biomolecules, 2023 - mdpi.com
Background: Epigenetics studies heritable or inheritable mechanisms that regulate gene
expression rather than altering the DNA sequence. However, no research has investigated …
expression rather than altering the DNA sequence. However, no research has investigated …
Multidimension analysis of the prognostic value, immune regulatory function, and ceRNA network of LY6E in individuals with colorectal cancer
T Li, W Liu, C Wang, M Wang, W Hui… - Journal of …, 2022 - Wiley Online Library
Background. Lymphocyte antigen 6 complex, locus E (LY6E) is abnormally expressed in
several cancers and is associated with poor outcomes. However, the biological role of LY6E …
several cancers and is associated with poor outcomes. However, the biological role of LY6E …
Emerging strategies of engineering and tracking dendritic cells for cancer immunotherapy
Y Gao, Z Wang, Y Cui, M Xu, L Weng - ACS Applied Bio Materials, 2022 - ACS Publications
Dendritic cells (DCs), a kind of specialized immune cells, play key roles in antitumor immune
response and promotion of innate and adaptive immune responses. Recently, many …
response and promotion of innate and adaptive immune responses. Recently, many …
Integrating single-cell and bulk RNA sequencing to predict prognosis and immunotherapy response in prostate cancer
XY Wen, RY Wang, B Yu, Y Yang, J Yang… - Scientific Reports, 2023 - nature.com
Prostate cancer (PCa) stands as a prominent contributor to morbidity and mortality among
males on a global scale. Cancer-associated fibroblasts (CAFs) are considered to be closely …
males on a global scale. Cancer-associated fibroblasts (CAFs) are considered to be closely …
Combination of pioglitazone and dendritic cell to optimize efficacy of immune cell therapy in CT26 tumor models
Introduction: The maturation faith of dendritic cells is restrained by the inflammatory
environment and cytokines, such as interleukin-6 and its downstream component. Therefore …
environment and cytokines, such as interleukin-6 and its downstream component. Therefore …
Exploring the Potential of Antibody-Drug Conjugates in Targeting Non-small Cell Lung Cancer Biomarkers
Antibody-drug conjugates (ADCs), combining the cytotoxicity of the drug payload with the
specificity of monoclonal antibodies, are one of the rapidly evolving classes of anti-cancer …
specificity of monoclonal antibodies, are one of the rapidly evolving classes of anti-cancer …
Dendritic cell-based immunotherapies and their potential use in colorectal cancer immunotherapy
AM Aldahlawi, ST Abdullah - Journal of Microscopy and …, 2022 - journals.lww.com
Dendritic cells (DCs) are professional antigen-presenting cells, which are resident or
proliferating in organs. Major histocompatibility complex (MHC) Class I and II on DCs in …
proliferating in organs. Major histocompatibility complex (MHC) Class I and II on DCs in …